Key result
The novel ASPS-1 cell line was successfully established, maintaining the t(X;17)(p11;q25) translocation and producing highly vascularized tumors in NOD.SCID/NCr mice.
The establishment of the ASPS-1 cell line provides a novel preclinical model that retains key features of alveolar soft part sarcoma to accelerate biological and therapeutic investigations.
Hypothesis-generating for alveolar soft part sarcoma therapies; leaves open clinical translation pending validation.
In vitro growth of alveolar soft part sarcoma (ASPS) and establishment of an ASPS cell line, ASPS-1, are described in this study. Using a recently developed xenograft model of ASPS derived from a lymph node metastasis, organoid nests consisting of 15 to 25 ASPS cells were isolated from ASPS xenograft tumors by capture on 70 μm filters and plated in vitro. After attachment to the substratum, these nests deposited small aggregates of ASPS cells. These cells grew slowly and were expanded over a period of 3 years and have maintained characteristics consistent with those of both the original ASPS tumor from the patient and the xenograft tumor including (1) presence of the alveolar soft part locus-transcription factor E3 type 1 fusion transcript and nuclear expression of the alveolar soft part locus-transcription factor E3 type 1 fusion protein; (2) maintenance of the t(X;17)(p11;q25) translocation characteristic of ASPS; and (3) expression of upregulated ASPS transcripts involved in angiogenesis (ANGPTL2, HIF-1-α, MDK, c-MET, VEGF, and TIMP-2), cell proliferation (PRL, PCSK1), metastasis (ADAM9), as well as the transcription factor BHLHB3 and the muscle-specific transcripts TRIM63 and ITGβ1BP3. This ASPS cell line forms colonies in soft agar and retains the ability to produce highly vascularized ASPS tumors in NOD.SCID/NCr mice. Immunohistochemistry of selected ASPS markers on these tumors indicated similarity to those of the original patient tumor as well as to the xenografted ASPS tumor. We anticipate that this ASPS cell line will accelerate investigations into the biology of ASPS including identification of new therapeutic approaches for treatment of this slow growing soft tissue sarcoma.
No takes yet. Share an insight, caveat, or question.
Kenney et al. (2011) studied Alveolar soft part sarcoma (ASPS). Establishment of ASPS-1 cell line was evaluated on Cell line characteristics and tumorigenicity. The novel ASPS-1 cell line was successfully established, maintaining the t(X;17)(p11;q25) translocation and producing highly vascularized tumors in NOD.SCID/NCr mice.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: